The effect of desmopressin on platelet function: A selective enhancement of procoagulant COAT platelets in patients with primary platelet function defects

Blood

Volumn 123, Issue 12, 2014, Pages 1905-1916

  Colucci, Giuseppe ^a   Stutz, Monika ^a   Rochat, Sophie ^a   Conte, Tiziana ^a   Pavicic, Marko ^a   Reusser, Marianne ^a   Giabbani, Evelyne ^a   Huynh, Anh ^a   Thur̈lemann, Charles ^a   Keller, Peter ^a   Alberio, Lorenzo ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; BLOOD CLOTTING FACTOR 8; CALCIUM ION; CONVULXIN; DESMOPRESSIN; DUAL SPECIFICITY PHOSPHATASE 2; FIBRINOGEN RECEPTOR; PADGEM PROTEIN; PROCOAGULANT; SODIUM ION; THROMBIN; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; CALCIUM TRANSPORT; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; HEMOSTASIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR MEMBRANE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; SODIUM TRANSPORT; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE DISORDER; THROMBOCYTE FUNCTION; VON WILLEBRAND DISEASE;

ADOLESCENT; ADULT; AGED; BLOOD PLATELET DISORDERS; BLOOD PLATELETS; CALCIUM; CYTOPLASMIC GRANULES; DEAMINO ARGININE VASOPRESSIN; FACTOR VIII; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET ADHESIVENESS; PLATELET AGGREGATION; PLATELET MEMBRANE GLYCOPROTEINS; SODIUM; THROMBIN; VON WILLEBRAND FACTOR; YOUNG ADULT;

EID: 84897561271     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-04-497123     Document Type: Article

References (55)

1. Richardson DW, Robinson AG. Desmopressin. Ann Intern Med. 1985;103(2):228-239. (Pubitemid 15000578)
2. Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. 1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases. Lancet. 1977;1(8017):869-872. (Pubitemid 8079684)
3. Kaufmann JE, Vischer UM. Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). J Thromb Haemost. 2003;1(4):682-689.
4. Kentro TB, Lottenberg R, Kitchens CS. Clinical efficacy of desmopressin acetate for hemostatic control in patients with primary platelet disorders undergoing surgery. Am J Hematol. 1987;24(2):215-219. (Pubitemid 17020789)
5. DiMichele DM, Hathaway WE. Use of DDAVP in inherited and acquired platelet dysfunction. Am J Hematol. 1990;33(1):39-45. (Pubitemid 20031291)
6. Rao AK, Ghosh S, Sun L, et al. Mechanisms of platelet dysfunction and response to DDAVP in patients with congenital platelet function defects. A double-blind placebo-controlled trial. Thromb Haemost. 1995;74(4):1071-1078.
7. Fuse I, Higuchi W, Aizawa Y. 1-deamino-8-D-arginine vasopressin (DDAVP) normalized the bleeding time in patients with platelet disorder characterized by defective calcium ionophore-induced platelet aggregation. Br J Haematol. 2003;122(5):870-871. (Pubitemid 37100319)
8. Fuse I, Higuchi W, Mito M, Aizawa Y. DDAVP normalized the bleeding time in patients with congenital platelet TxA2 receptor abnormality. Transfusion. 2003;43(5):563-567. (Pubitemid 36506350)
9. Coppola A, Di Minno G. Desmopressin in inherited disorders of platelet function. Haemophilia. 2008;14(Suppl 1):31-39.
10. Tosetto A, Balduini CL, Cattaneo M, et al Italian Society for Haemostasis and Thrombosis. Management of bleeding and of invasive procedures in patients with platelet disorders and/or thrombocytopenia: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thromb Res. 2009;124(5):e13-e18.
11. Cattaneo M. Desmopressin in the treatment of patients with defects of platelet function. Haematologica. 2002;87(11):1122-1124. (Pubitemid 35397767)
12. Cattaneo M, Moia M, Delle Valle P, Castellana P, Mannucci PM. DDAVP shortens the prolonged bleeding times of patients with severe von Willebrand disease treated with cryoprecipitate. Evidence for a mechanism of action independent of released von Willebrand factor. Blood. 1989;74(6):1972-1975. (Pubitemid 19269096)
13. Lethagen S, Nilsson IM. DDAVP-induced enhancement of platelet retention: its dependence on platelet-von Willebrand factor and the platelet receptor GP IIb/IIIa. Eur J Haematol. 1992;49(1):7-13.
14. Greinacher A, Pötzsch B, Kiefel V, White JG, Müller-Berghaus G, Mueller-Eckhardt C. Evidence that DDAVP transiently improves hemostasis in Bernard-Soulier syndrome independent of von Willebrand-factor. Ann Hematol. 1993;67(3):149-150. (Pubitemid 23274231)
15. Noris P, Arbustini E, Spedini P, Belletti S, Balduini CL. A new variant of Bernard-Soulier syndrome characterized by dysfunctional glycoprotein (GP) Ib and severely reduced amounts of GPIX and GPV. Br J Haematol. 1998;103(4):1004-1013. (Pubitemid 29012636)
16. Mannucci PM, Vicente V, Vianello L, et al. Controlled trial of desmopressin in liver cirrhosis and other conditions associated with a prolonged bleeding time. Blood. 1986;67(4):1148-1153. (Pubitemid 16116433)
17. Schulman S, Johnsson H, Egberg N, Blombäck M. DDAVP-induced correction of prolonged bleeding time in patients with congenital platelet function defects. Thromb Res. 1987;45(2):165-174. (Pubitemid 17008084)
18. Balduini CL, Noris P, Belletti S, Spedini P, Gamba G. In vitro and in vivo effects of desmopressin on platelet function. Haematologica. 1999;84(10):891-896. (Pubitemid 29516919)
19. Alberio L, Safa O, Clemetson KJ, Esmon CT, Dale GL. Surface expression and functional characterization of alpha-granule factor V in human platelets: effects of ionophore A23187, thrombin, collagen, and convulxin. Blood. 2000;95(5):1694-1702. (Pubitemid 30120831)
20. Dale GL, Friese P, Batar P, et al. Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface. Nature. 2002;415(6868):175-179. (Pubitemid 34059519)
21. Mazepa M, Hoffman M, Monroe D. Superactivated platelets: thrombus regulators, thrombin generators, and potential clinical targets. Arterioscler Thromb Vasc Biol. 2013;33(8):1747-1752.
22. Rao AK, Jalagadugula G, Sun L. Inherited defects in platelet signaling mechanisms. Semin Thromb Hemost. 2004;30(5):525-535. (Pubitemid 39426385)
23. Zürcher M, Sulzer I, Barizzi G, Lämmle B, Alberio L. Stability of coagulation assays performed in plasma from citrated whole blood transported at ambient temperature. Thromb Haemost. 2008;99(2):416-426. (Pubitemid 351230974)
24. Favaloro EJ. Utility of the PFA-100 for assessing bleeding disorders and monitoring therapy: a review of analytical variables, benefits and limitations. Haemophilia. 2001;7(2):170-179. (Pubitemid 32243800)
25. Thommen D, Sulzer I, Buhrfeind E, Naef R, Furlan M, Lämmle B. Measurement of bleeding time and study of thrombocyte aggregation. Standardization of methods, normal values and results in patients with suspected hemorrhagic diathesis [in German]. Schweiz Med Wochenschr. 1988;118(43):1559- 1567.
26. Wall JE, Buijs-Wilts M, Arnold JT, et al. A flow cytometric assay using mepacrine for study of uptake and release of platelet dense granule contents. Br J Haematol. 1995;89(2):380-385.
27. Hemker HC, Giesen P, Al Dieri R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003;33(1):4-15. (Pubitemid 37449290)
28. Monteiro M-d-C, Gonçalves M-J, Sansonetty F, O'Connor J-E. 2003. Flow cytometric analysis of calcium mobilization in whole-blood platelets. Current Protocols in Cytometry. 24:9.20.1-9.20.8.
29. Keularts IM, Hamulyak K, Hemker HC, Béguin S. The effect of DDAVP infusion on thrombin generation in platelet-rich plasma of von Willebrand type 1 and in mild haemophilia A patients. Thromb Haemost. 2000;84(4):638-642.
30. Tsakiris DA, Haefeli WE, Linder L, Steiner B, Marbet GA. Platelet surface activation markers after DDAVP infusion in healthy subjects. Thromb Haemost. 1995;74(3):991-992.
31. Ghosh S, Rao AK. Lack of effect of 1-desamino-8-D-arginine vasopressin on direct adhesion of platelets to collagen. Thromb Res. 1993;70(5):417-422. (Pubitemid 23171428)
32. Yang X, Disa J, Rao AK. Effect of 1-desamino-8-D-arginine vasopressin (DDAVP) on human platelets. Thromb Res. 1990;59(5):809-818. (Pubitemid 20314049)
33. Tauer JT, Gneuss A, Lohse JE, Jürgens T, Knöfler R. Evaluation of desmopressin effect on primary haemostasis in pediatric patients with aspirin-like defect as hereditary thrombocytopathy. Klin Padiatr. 2011;223(3):169-172.
34. De Marco L, Girolami A, Zimmerman TS, Ruggeri ZM. von Willebrand factor interaction with the glycoprotein IIb/IIa complex. Its role in platelet function as demonstrated in patients with congenital afibrinogenemia. J Clin Invest. 1986;77(4):1272-1277. (Pubitemid 16047149)
35. Kasirer-Friede A, Ware J, Leng L, Marchese P, Ruggeri ZM, Shattil SJ. Lateral clustering of platelet GP Ib-IX complexes leads to upregulation of the adhesive function of integrin alpha IIbbeta 3. J Biol Chem. 2002;277(14):11949- 11956. (Pubitemid 34952754)
36. Kaufmann JE, Iezzi M, Vischer UM. Desmopressin (DDAVP) induces NO production in human endothelial cells via V2 receptor- and cAMP-mediated signaling. J Thromb Haemost. 2003;1(4):821-828.
37. Egberg N. Effect of venous occlusion and DDAVP injection on platelet aggregation and platelet cyclic AMP. Thromb Res. 1980;19(1-2):263-265. (Pubitemid 10014471)
38. Smolenski A. Novel roles of cAMP/cGMP-dependent signaling in platelets. J Thromb Haemost. 2012;10(2):167-176.
39. Hezard N, Jallu V, Garnotel R, Kaplan C, Nguyen P. DDAVP infusion can modify VASP phosphorylation in human platelets. J Thromb Haemost. 2004;2(4):672-673. (Pubitemid 40185694)
40. Giannini S, Mezzasoma AM, Leone M, Gresele P. Laboratory diagnosis and monitoring of desmopressin treatment of von Willebrand's disease by flow cytometry. Haematologica. 2007;92(12):1647-1654. (Pubitemid 350248244)
41. Heemskerk JW, Mattheij NJ, Cosemans JM. Platelet-based coagulation: different populations, different functions. J Thromb Haemost. 2013;11(1):2-16.
42. Horstman LL, Valle-Riestra BJ, Jy W, Wang F, Mao W, Ahn YS. Desmopressin (DDAVP) acts on platelets to generate platelet microparticles and enhanced procoagulant activity. Thromb Res. 1995;79(2):163-174.
43. Kaufmann JE, Oksche A, Wollheim CB, Günther G, Rosenthal W, Vischer UM. Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP. J Clin Invest. 2000;106(1):107-116. (Pubitemid 30437246)
44. Rembratt A, Graugaard-Jensen C, Senderovitz T, Norgaard JP, Djurhuus JC. Pharmacokinetics and pharmacodynamics of desmopressin administered orally versus intravenously at daytime versus night-time in healthy men aged 55-70 years. Eur J Clin Pharmacol. 2004;60(6):397-402. (Pubitemid 39214892)
45. Brown D, Hasler U, Nunes P, Bouley R, Lu HA. Phosphorylation events and the modulation of aquaporin 2 cell surface expression. Curr Opin Nephrol Hypertens. 2008;17(5):491-498.
46. Rinschen MM, Yu MJ, Wang G, et al. Quantitative phosphoproteomic analysis reveals vasopressin V2-receptor-dependent signaling pathways in renal collecting duct cells. Proc Natl Acad Sci USA. 2010;107(8):3882-3887.
47. Bankir L, Fernandes S, Bardoux P, Bouby N, Bichet DG. Vasopressin-V2 receptor stimulation reduces sodium excretion in healthy humans. J Am Soc Nephrol. 2005;16(7):1920-1928. (Pubitemid 41716422)
48. Gamba G. Vasopressin regulates the renal Na+-Cl- cotransporter. Am J Physiol Renal Physiol. 2010;298(3):F500-F501.
49. Tani M, Neely JR. Na1 accumulation increases Ca2+ overload and impairs function in anoxic rat heart. J Mol Cell Cardiol. 1990;22(1):57-72. (Pubitemid 20108000)
50. Palty R, Sekler I. The mitochondrial Na(+)/Ca(2+) exchanger. Cell Calcium. 2012;52(1):9-15.
51. Heemskerk JW, Vuist WM, Feijge MA, Reutelingsperger CP, Lindhout T. Collagen but not fibrinogen surfaces induce bleb formation, exposure of phosphatidylserine, and procoagulant activity of adherent platelets: evidence for regulation by protein tyrosine kinase-dependent Ca2+ responses. Blood. 1997;90(7):2615-2625. (Pubitemid 27413471)
52. Mahaut-Smith MP. A role for platelet TRPC channels in the Ca2+ response that induces procoagulant activity. Sci Signal. 2013;6(281):pe23.
53. Harper MT, Londoño JE, Quick K, et al. Transient receptor potential channels function as a coincidence signal detector mediating phosphatidylserine exposure. Sci Signal. 2013;6(281):ra50.
54. Kerbiriou-Nabias D, Arachiche A, Dachary-Prigent J. Phosphatidylserine exposure and calcium-activated potassium efflux in platelets. Br J Haematol. 2011;155(2):268-270.
55. Tomasiak MM, Stelmach H, Bodzenta-Łukaszyk A, Tomasiak M. Involvement of Na+/H+ exchanger in desmopressin-induced platelet procoagulant response. Acta Biochim Pol. 2004;51(3):773-788. (Pubitemid 39296930)